437O KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50%
Martin Reck, D. Rodríguez-Abreu, AE Robinson et al. · Annals of Oncology · 2016
Cited by 5 works. doi:10.1093/annonc/mdw594.001